Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07275315 in Moderate-to-Severe COPD (Phase 2/3, Japan)
jRCT2061250099Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of tilrekimig in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Pfizer. Primary endpoints: Phase 2: Change from baseline in pre-bronchodilator FEV1 at Week 24 and Phase 3: Annualized rate of moderate or severe ECOPD. Started Apr 2026; status: recruiting.
02
Drugs
tilrekimig
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2061250099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250099.